Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 1

Etanercept in the treatment of rheumatoid arthritis

Authors Boulos Haraoui, Vivian Bykerk

Published 15 March 2007 Volume 2007:3(1) Pages 99—105

Boulos Haraoui1, Vivian Bykerk2

1Clinical Associate Professor of Medicine, University of Montreal, Montreal Canada; 2Associate Professor of Medicine, University of Toronto, Toronto Canada

Abstract: Etanercept (ETN) is the first anti-tumor necrosis factor (TNF) agent to be approved for the treatment of rheumatoid arthritis (RA). Over the last 8 years, several clinical trials have shown its efficacy and safety in established and early RA, as well as a monotherapy or in combination with methotrexate. ETN not only reduces the signs and symptoms of RA, but also retards the progression of radiographic damage and improves the quality of life and function of patients. Its safety profile has been predictable since the first clinical trials with no new major safety concerns. Beyond its efficacy in RA, ETN is also indicated for the treatment of psoriatic arthritis. This current report reviews the evidence and the data in RA and psoriatic arthritis (PsA).

Keywords: etanercept, tumor necrosis factor-α, rheumatoid arthritis, psoriatic arthritis

Download Article [PDF] 

Readers of this article also read:

Life-threatening hemorrhage following subcutaneous heparin therapy

Jana Hudcova, Daniel Talmor

Therapeutics and Clinical Risk Management 2009, 5:51-54

Published Date: 2 December 2008

Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki

Geoffrey S Dow, Alan J Magill, Colin Ohrt

Therapeutics and Clinical Risk Management 2008, 4:803-819

Published Date: 8 August 2008

Obstructive sleep apnea and cardiovascular risk

Punginathn Dorasamy

Therapeutics and Clinical Risk Management 2007, 3:1105-1111

Published Date: 15 January 2008

Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study

Gian Luigi Marseglia, Mariangela Tosca, Ignazio Cirillo, Amelia Licari, Maddalena Leone, Alessia Marseglia, Anna Maria Castellazzi, Giorgio Ciprandi

Therapeutics and Clinical Risk Management 2007, 3:13-17

Published Date: 15 March 2007

Comparison of echinocandin antifungals

Gregory Eschenauer, Daryl D DePestel, Peggy L Carver

Therapeutics and Clinical Risk Management 2007, 3:71-97

Published Date: 15 March 2007

What do parents want from their child's asthma treatment?

Stefan Walzer

Therapeutics and Clinical Risk Management 2007, 3:167-175

Published Date: 15 March 2007

Editorial ||FREE PAPER||

Garry Walsh

Therapeutics and Clinical Risk Management 2006, 2:335-336

Published Date: 15 December 2006